1.

培美曲塞治疗晚期非鳞型NSCLC的临床特征与疗效的相关性

The relationship between the clinical characteristic and efficacy of pemetrexed in advanced non-squamous NSCLC

Characteristic	n	ORR [n (%)]	P	DCR [n (%)]	P
ORR: objective response rate; DCR: disease control rate; NSCLC: non-small cell lung cancer.
Gender			0.999		0.425
Male	21	3 (14.29)		11 (52.38)
Female	25	4 (16.00)		16 (64.00)
Age (year)			0.653		0.655
＜60	26	5 (19.23)		16 (61.54)
≥60	20	2 (10.00)		11 (55.00)
Smoking history			0.420		0.382
Ever smokers	16	1 (6.25)		19 (63.33)
Never smokers	30	6 (20.00)		8 (50.00)
Therapy			0.999		0.999
Third-line therapy	29	4 (13.79)		17 (58.62)
Beyond third-line therapy	17	3 (17.65)		10 (58.82)
Chemotherapy regimens			0.079		0.043
Pemetrexed	15	1 (6.67)		5 (33.33)
Pemetrexed plus carboplatin	20	2 (10.00)		15 (75.00)
Pemetrexed plus cisplatin	11	4 (36.36)		7 (63.34)